Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ophtha.2015.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ruthenium-106 brachytherapy and central uveal melanoma.
Int Ophthalmol
January 2025
Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Purpose: Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.
View Article and Find Full Text PDFA retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience.
Brachytherapy
January 2025
Ocular Oncology and Radiology Department, S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.
Purpose: To retrospectively evaluate the efficacy of plaque brachytherapy for the treatment of retinoblastoma.
Methods: We retrospectively reviewed the clinical records of 163 patients (186 eyes, 333 tumors) treated with brachytherapy (Ru or Sr plaques) for intraocular retinoblastoma between November 2007 and August 2023.
Results: Complete tumor control was achieved in 273 tumors (82%).
Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting.
Ocul Oncol Pathol
December 2024
Ophthalmology Department, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Introduction: Clear evidence for the best clinical management of uveal melanoma is lacking in some areas. Therefore, reports on expert opinions in the field can be valuable.
Methods: A questionnaire comprising 10 questions was distributed to potential participants of the 58th Ophthalmic Oncology Group Meeting in Stockholm, Sweden, in June 2024.
Ruthenium-106 (Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy.
Brachytherapy
November 2024
The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Road no 2, Banjara Hills, Hyderabad, 500034 India.
Purpose: To describe the clinical presentation and treatment outcomes of patients undergoing Ruthenium-106 (Ru) plaque brachytherapy as salvage treatment for retinoblastoma (RB) following intravenous chemotherapy (IVC).
Methods: Retrospective chart review of 44 eyes of 42 patients. The indications for plaque brachytherapy included solid tumor recurrence (n=20; 45%), solid tumor residual (n=16; 36%), new subretinal seeds (n=5; 12%), and new solid tumor (n=3; 7%).
Plaque Radiotherapy for Ocular Melanoma.
Cancers (Basel)
October 2024
Department of Ophthalmology, National University Health System, Singapore 119228, Singapore.
Article Synopsis
- Plaque radiotherapy is a targeted treatment for medium-sized ocular tumors like uveal melanoma, using customized plaques to deliver precise radiation while minimizing damage to surrounding healthy tissue.
- The choice of radioisotope, such as Ruthenium-106 or Iodine-125, is based on factors like tumor characteristics and desired treatment duration, with high dose rate (HDR) options facilitating quicker treatment.
- Efficacy of Ruthenium-106 varies significantly, and outcomes can be influenced by tumor size, thickness, and location; however, plaque brachytherapy can offer similar survival rates to more invasive treatments like enucleation for suitable cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!